ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or
“IPA” or the “Company”), a leader in AI-driven biotherapeutic
research and technology, is thrilled to announce that its
subsidiary, BioStrand®, has published a preprint of its
groundbreaking white paper titled, "New Paradigm for Biological
Sequence Retrieval Inspired by Natural Language Processing and
Database Research" on bioRχiv.
The publication delves into the intricacies of one of
BioStrand’s applications based on its patented HYFT-based
methodology, a novel and proprietary approach to biological
sequence retrieval, and its clear advantages over the gold standard
algorithm, Basic Local Alignment Search Tool “BLAST”. By detailing
their innovative approach and its potential implications for the
scientific community, BioStrand aims to foster collaboration and
drive innovation in the realm of bioinformatics.
Key Highlights from the White Paper:
- Introduction to HYFT Patterns: The paper introduces HYFT
patterns as unique signature sequences, akin to biological
fingerprints, found in amino acids, DNA, and RNA. These patterns
serve as a tool to tokenize and harmonize all biological data into
a unified omics language.
- Parsing and Indexing with HYFTs: The paper details the two-step
process of parsing biological sequences to retrieve HYFT patterns
and then indexing them. This approach prioritizes non-overlapping
HYFTs with lower ranks, ensuring comprehensive coverage of the
sequence.
- Benchmarking Results: A comparative study between BLAST and the
HYFT methodology revealed that while BLAST excels in retrieving
distant homologous sequences, HYFT is particularly relevant for
higher identity matches.
Dirk Van Hyfte, MD, PhD, Co-Founder and Head of Innovation of
BioStrand, remarked, "The publication of our research on
biorxiv.org is not just a milestone for BioStrand, but a
significant contribution to the bioinformatics community. We
believe, given the ever-increasing availability of sequence data,
our HYFT-based sequence similarity search methodology offers the
scalability needed in this era of Big Data without losing
precision, and we eagerly anticipate the discourse and
collaboration it will inspire."
LENSai: The Next-Generation Advanced AI Platform
Recently, BioStrand successfully rolled out its next-generation
unified knowledge graph-Large Language Model (LLM) framework for
holistic life sciences research. At the core of their LENSai
platform is a comprehensive and continuously expanding knowledge
graph that maps a remarkable 25 billion relationships across 660
million data objects, linking sequence, structure, function, and
literature information from the entire biosphere. Their
first-in-class technology provides a comprehensive understanding of
the relationships between genes, proteins, structures, and
biological pathways, thereby opening powerful new opportunities for
drug discovery and development. The platform leverages the latest
advances in ontology-driven NLP and AI-driven LLMs to connect and
correlate syntax (multi-modal sequential and structural data) and
semantics (biological functions). BioStrand’s unified approach to
biomedical knowledge graphs, Retrieval Augmented Generation (RAG)
models, and LLMs combines the reasoning capabilities of LLMs, the
semantic proficiency of knowledge graphs, and the versatile
information retrieval capabilities of RAG, to streamline the
integration, exploration, and analysis of biomedical data,
potentially unlocking a realm of uncharted possibilities.
About ImmunoPrecise Antibodies Ltd
ImmunoPrecise Antibodies Ltd. has several subsidiaries in North
America and Europe including entities such as Talem Therapeutics
LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd., and
ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA
Family”). The IPA Family is a biotherapeutic research and
technology group that leverages systems biology, multi-omics
modeling, and complex artificial intelligence systems to support
its proprietary technologies in bioplatform-based antibody
discovery. Services include highly specialized, full-continuum
therapeutic biologics discovery, development, and out-licensing to
support its business partners in their quest to discover and
develop novel biologics against the most challenging targets. For
further information, visit www.ipatherapeutics.com.
Forward Looking Information
This news release contains forward-looking statements within the
meaning of applicable United States securities laws and Canadian
securities laws. Forward-looking statements are often identified by
the use of words such as “potential”, “plans”, “expects” or “does
not expect”, “is expected”, “estimates”, “intends”, “anticipates”
or “does not anticipate”, or “believes”, or variations of such
words and phrases or state that certain actions, events or results
“may”, “could”, “would”, “might” or “will” be taken, occur or be
achieved. Forward-looking information contained in this news
release includes, but is not limited to, statements relating to the
expected outcome on the market, the life sciences, drug discovery
and development, integration and / or success of LENSai, LLMs, RAG,
or HYFT technologies, and statements relating to IPA’s expected
increased revenue streams and financial growth. In respect of the
forward-looking information contained herein, IPA has provided such
statements and information in reliance on certain assumptions that
management believed to be reasonable at the time.
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of IPA’s LENSai platform
with its HYFT technology may not have the expected results,
Forward-looking information involves known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements stated herein to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks, including, without
limitation, the risk that the integration of IPA’s LENSai platform
with its HYFT technology may not have the expected results, actual
results could differ materially from those currently anticipated
due to a number of factors and risks, as discussed in the Company’s
Annual Information Form dated July 10, 2023 (which may be viewed on
the Company’s profile at www.sedar.com), and the Company’s Form
40-F, dated July 10, 2023 (which may be viewed on the Company’s
profile at www.sec.gov). Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking statements prove incorrect, actual results,
performance, or achievements may vary materially from those
expressed or implied by the forward-looking statements contained in
this news release. Accordingly, readers should not place undue
reliance on forward-looking information contained in this news
release. The forward-looking statements contained in this news
release are made as of the date of this release and, accordingly,
are subject to change after such date. The Company does not assume
any obligation to update or revise any forward-looking statements,
whether written or oral, that may be made from time to time by us
or on our behalf, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231113700781/en/
Investors: investors@ipatherapeutics.com
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From Apr 2024 to May 2024
ImmunoPrecise Antibodies (NASDAQ:IPA)
Historical Stock Chart
From May 2023 to May 2024